Cargando…

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer

BACKGROUND: The majority of chemoradiation (CRT) trials for locally advanced head and neck squamous cell carcinoma (HNSCC) have relied on platinum-based chemotherapy regimens administered every-3-weeks. However, given the increased utilization of weekly platinum regimens, it remains unclear how diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melotek, James M., Cooper, Benjamin T., Koshy, Matthew, Silverman, Joshua S., Spiotto, Michael T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121964/ https://www.ncbi.nlm.nih.gov/pubmed/27881143 http://dx.doi.org/10.1186/s40463-016-0175-x

Ejemplares similares

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer
por: Ameri, Ahmad, et al.
Publicado: (2021)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?
por: Mashhour, Karim, et al.
Publicado: (2020)

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
por: Schaeffers, Anouk W. M. A., et al.
Publicado: (2023)

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study
por: Mathur, Akash, et al.
Publicado: (2018)

A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis
por: Sprenger, Anarosa B., et al.
Publicado: (2019)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients
por: Buglione, Michela, et al.
Publicado: (2021)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Commentary on “Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data”
por: Colevas, A. Dimitrios
Publicado: (2017)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma
por: Tao, Chang-Juan, et al.
Publicado: (2014)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers
por: Spiotto, Michael T., et al.
Publicado: (2014)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

As every year, 2016 ended with the Council Week
por: Staff Association
Publicado: (2017)

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)
por: Guan, Jian, et al.
Publicado: (2016)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Machine Learning–Guided Adjuvant Treatment of Head and Neck Cancer
por: Howard, Frederick Matthew, et al.
Publicado: (2020)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis
por: Lee, So Yeon, et al.
Publicado: (2018)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

One Bulletin printed every two weeks, but updated weekly on-line, equals the same quantity of information as a weekly printed Bulletin.
por: Stephane Viollet
Publicado: (2005)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation
por: Russi, Elvio G., et al.
Publicado: (2014)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
por: Helfenstein, Seth, et al.
Publicado: (2019)

Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
por: Vaugier, Loïg, et al.
Publicado: (2021)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma
por: Nanda, R., et al.
Publicado: (2019)

Weekly vs. tri-weekly cisplatin based chemoradiation in carcinoma cervix: a prospective randomized study of toxicity and compliance
por: Katke, Aradhana, et al.
Publicado: (2021)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles
por: SORBE, BENGT, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hk05fnjaru9t8ho6m210eof848